Clinical trials: Inflammatory Bowel Diseases
Crohn's Disease
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease
The study hypothesis is to establish the safety and tolerability of long-term open-label (OL) CP-690,550 therapy in subjects with Crohn's disease.
- Trial name
- NCT01470599
- Testing
- CP-690,550
- Where
- 75 sites in United States, Australia and 15 more
- Volunteers
- 150 people
- Sponsor
- Pfizer
Crohn's Disease
Phase III Study of D9421-C 9 mg in Patients With Active Crohn's Disease in Japan
The purpose of this study is to evaluate the clinical efficacy of D9421-C 9 mg once daily compared to Mesalazine 1 g three times a day to patients with mild to moderate active Crohn's disease affecting ileum, ileocecal region…
- Trial name
- NCT01514240
- Testing
- D9421-C capsule 3 mg, Mesalazine tablets
- Where
- 25 sites in Japan
- Volunteers
- 123 people
- Sponsor
- AstraZeneca
Ulcerative Colitis
Hyperbaric Oxygen for Ulcerative Colitis
The investigators aim to prospectively study the feasibility and clinical impact of hyperbaric oxygen therapy in acute hospitalized moderate to severe ulcerative colitis flares as an adjunct to standard medical treatment.
- Trial name
- NCT02144350
- Testing
- Hyperbaric oxygen
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Colorectal Neoplasms
A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer
This open-label, prospective, single-arm, multicenter study will evaluate the relationship of the markers of inflammation and progression-free survival (PFS) in participants with previously untreated metastatic colorectal cancer.
- Trial name
- ASCENT (NCT01588990)
- Testing
- Oxaliplatin, Capecitabine, Bevacizumab
- Where
- 17 sites in Australia
- Volunteers
- 128 people
- Sponsor
- Hoffmann-La Roche
Crohn Disease, Ulcerative Colitis
National Observational Study On The Use Of Inflectra™ An Infliximab Biosimilar In Real Life
National, prospective, multicentre observational study designed for eligible patients treated with Inflectra. Its objectives are to describe under real conditions of use, the profile of patients treated with Inflectra and the…
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- ReFLECT (NCT02925338)
- Testing
- QOL questionaire
- Where
- 67 sites in France
- Volunteers
- 1,431 people
- Sponsor
- Pfizer
Crohn's Disease
Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE)
The primary objective of this study is to make adalimumab available to patients suffering from moderately to severely active Crohn's Disease who have failed to respond to, lost response to, or are intolerant to infliximab, and to…
- Trial name
- NCT00338650
- Testing
- adalimumab
- Where
- 97 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Abbott
Ulcerative Colitis
Once Daily Versus Conventional Dosing of Asacol in the Maintenance of Quiescent Ulcerative Colitis
The purpose of this study is to determine if taking Asacol once a day is as effective as taking Asacol twice or three times a day in keeping ulcerative colitis inactive, and to determine which dosing regimen is easiest to follow.
- Trial name
- NCT00343850
- Testing
- Asacol (mesalamine)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Chicago
Ulcerative Colitis (UC), Crohn Disease (CD)
The Safety and Efficacy of Good Feeling Power® for IBD Patients
This open-label pilot study aims to evaluate the safety and efficacy of the dietary supplement Good Feeling Power® for patients with mild-to-moderate ulcerative colitis and colonic/ileal Crohn's disease.
- Trial name
- NCT07766733
- Testing
- Good Feeling Power®
- Where
- Spain
- Volunteers
- 36 people
- Sponsor
- Good Feeling Products GmbH
Inflammation, Crohn's Disease
The Effects of Naltrexone on Active Crohn's Disease
It is hypothesized that the opioid antagonist naltrexone will improve inflammation of the bowel and quality of life in subjects with active Crohn's disease compared to placebo.
- Trial name
- LDN (NCT00663117)
- Testing
- Naltrexone-HCl
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Milton S. Hershey Medical Center
Crohn Disease (CD)
The Utility of Hand-held Ultrasound Devices to Detect Bowel Wall Inflammatory Activity in Crohn's Disease
One of the major obstacles in implementing intestinal ultrasound services for inflammatory bowel disease (IBD) patients relates to the costs of acquiring ultrasound (US) machines.
- Trial name
- NCT06686589
- Testing
- Intestinal ultrasound
- Volunteers
- 150 people
- Sponsor
- Sheba Medical Center
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Periodontal Diseases, IBD
Periodontal Therapy on the Gut Microbiome of Inflammatory Bowel Disease
Periodontitis and inflammatory bowel disease have been associated by meta-epidemiologic evidence, although their mechanistic connection needs to be further explored.
- Conditions
- Periodontal Diseases, IBD, Dysbiosis, Inflammation
- Trial name
- NCT04790825
- Testing
- Full mouth scaling and root planing (FMSRP)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- University of Turin, Italy
Crohn Disease
A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through less than (<) 18 years old in the USA, or 6 through less than (<) 18 years old in other countries and determine if it is…
- Trial name
- STELARA (NCT02968108)
- Testing
- Ustekinumab
- Where
- 26 sites in United States, Belgium and 4 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Feeding; Difficult, Newborn, Growth Failure
Prophylactic Probiotics to Extremely Low Birth Weight Prematures
Mortality and incidence of severe complications is still high among extremely premature infants. Common causes of severe complications in this population are poor nutrition, necrotizing enterocolitis, and severe infections.
- Conditions
- Feeding; Difficult, Newborn, Growth Failure, Necrotizing Enterocolitis, Sepsis
- Trial name
- PROPEL (NCT01603368)
- Testing
- Lactobacillus reuteri
- Where
- 2 sites in Sweden
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Ostergotland County Council, Sweden
Pouchitis, Inflammatory Bowel Diseases
Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis
Patients with chronic pouchitis is disabled by bloody diarrhoea and abdominal pain often followed by fever. Pouchitis is an inflammation in a pouch, a reservoir formed by the small intestine in the management of the chronic…
- Conditions
- Pouchitis, Inflammatory Bowel Diseases, Ulcerative Colitis
- Trial name
- NCT04820413
- Testing
- Faecal microbiota transplantation
- Where
- Denmark
- Volunteers
- 3 people
- Sponsor
- Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery
Inflammatory Bowel Disease (IBD)
Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease
The aim of this therapeutic trial is to compare the response of subjects with active IBD to daily intravenous dexamethasone versus the response to daily intravenous methylprednisolone.
- Trial name
- NCT00152620
- Testing
- Dexamethasone, Methylprednisolone
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Chicago
Cirrhosis, Acquired Portal-systemic Shunt Due to Cirrhosis
Effect of Transjugular Intrahepatic Portosystemic Shunt on Gut Microbiota in Cirrhotic Patients
The purpose of this study is to determine the effect of transjugular intrahepatic portosystemic shunt on gut microbiota and associated inflammatory factors in cirrhotic patients.
- Conditions
- Cirrhosis, Acquired Portal-systemic Shunt Due to Cirrhosis, Hepatic Encephalopathy
- Trial name
- NCT02427906
- Where
- China
- Volunteers
- 50 people
- Sponsor
- West China Hospital
Crohn's Disease
Development of Niv Score of Capsule Endoscopy in Patients With Crohn's (CECDAIic)
Hypothesis This study is designed as an integral part of the development of a new CE score for Crohn's disease. The SB (small bowel) CD (Crohn's Disease)Niv score (CECDAI) is an established and validated CD score for SB…
- Trial name
- NCT01793376
- Volunteers
- 30 people
- Sponsor
- Medtronic - MITG
Ulcerative Colitis
New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis
The purpose of this study is to establish the efficacy and safety of a new tablet formulation and dosing regimen of balsalazide disodium dosed twice daily in achieving clinical improvement in subjects with mildly to moderately…
- Trial name
- NCT00269438
- Testing
- 5 ASA, enemas, suppositories, corticosteroids
- Where
- 66 sites in United States
- Volunteers
- 225 people, healthy volunteers welcome
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis, Inflammatory Bowel Diseases
Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis
The goal of this clinical trial is to learn if combined therapy with infliximab and ustekinumab works better than using these drugs alone in adult patients with ulcerative colitis.
- Trial name
- COMBO-UC (NCT06453317)
- Testing
- Infliximab, Ustekinumab
- Where
- Poland
- Volunteers
- 172 people
- Sponsor
- Medical University of Lodz
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.